



CURRICULUM VITAE

Vinod Ravi, M.D., MBA

PRESENT TITLE AND AFFILIATION

Primary Appointment

Associate Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Clinical Medical Director, Translational Research Accelerator, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Director, University of Texas – Health Intelligence Platform (UT-HIP)

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

CITIZENSHIP

United States

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center

1400 Holcombe Blvd.

Sarcoma Medical Oncology

Unit Number: 450

Houston, TX 77030

Room Number: FC12.3044

Phone: 713-792-3626

Fax: 713-794-1934

Email: vravi@mdanderson.org

EDUCATION

Degree-Granting Education

Medical College Trivandrum, University of Kerala, Kerala, India, MD, 1998, Medicine and Surgery

School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, MS, 2001, Epidemiology - Clinical Epidemiology

Jones Graduate School of Business at Rice University, Houston, TX, MBA, Jones Scholar, 2019, Healthcare Administration

Postgraduate Training

Clinical Internship, Internal Medicine, St. Vincent's Medical Center - Columbia University College of Physicians and Surgeons, Bridgeport, CT, 7/2001-6/2002

Clinical Residency, Internal Medicine, St. Vincent's Medical Center - Columbia University College of Physicians and Surgeons, Bridgeport, CT, 7/2002-6/2004

Clinical Fellowship, Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, 7/2004-6/2007

Physician Builder Certification, Epic University, Madison, WI, 2015-2016

Faculty Leadership Academy, UT MD Anderson Cancer Center, HOUSTON, TX, 8/2016-5/2017

Physician Builder - Analytics, Epic University, Madison, WI, 5/2017-5/2017

CREDENTIALS

Board Certification

American Board of Internal Medicine - General, 228274, 8/2004-12/2014

American Board of Internal Medicine - Medical Oncology, 228274, 11/2007-12/2017

Licensures

Active

Educational Commission for Foreign Graduates, 06157515, 8/2000

Texas Medical Board, TX, M9599, 4/2008-11/2021

Inactive

New York Medical Board, NY, 002897, 7/2007-7/2009

EXPERIENCE/SERVICE

Academic Appointments

Visiting Associate Research Scientist, Molecular Medicine, Columbia University College of Physicians and Surgeons, New York City, NY, 7/2001-6/2004

Adjunct Faculty, Translational Genomics Research Institute, Phoenix, AZ, 10/2006-2/2007

Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, 7/2007-6/2008

Assistant Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 6/2008-8/2014

Associate Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2014-present

Associate Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2016-present

Administrative Appointments/Responsibilities

Leiomyosarcoma Working Group Chair, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2013-6/2016

Angiosarcoma Working Group Chair, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2013-present

Team Lead, EPIC sarcoma build, MD Anderson Cancer Center, Houston, TX, 7/2014-present

EPIC Physician Builder, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2015-present

Clinical Medical Director, Translational Research Accelerator, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2016-present

Research Director, University of Texas Health Intelligence Platform, Houston, TX, 7/2021-present

Other Appointments/Responsibilities

Medical Oncology Fellow, Roswell Park Cancer Institute, Buffalo, NY, 7/2004-6/2007

Institutional Committee Activities

Faculty Senate, Member, 2009-2015

ECMS Committee, Member, 2009-present

DECODE data effort: Operations committee member and Data office lead, Committee Member, 2019-present

Data Analytics Reporting and Informatics Committee, Committee Member, 2019-present

HONORS AND AWARDS

Outstanding Academic Achievement Award, Medical College Trivandrum, 1998
Gold Medal in Pharmacology, Medical College Trivandrum, 1999
Humanitarian Award, St. Vincent's Medical Center, 2003-2004
2004 Critical Care House Officer Award, St. Vincent's Medical Center, 2004
2007 Best Basic Science Research, Roswell Park Cancer Institute, 2007
US NEWS TOP DOCTOR, 2012-2013
US NEWS TOP DOCTOR, 2013-2014
Castle Connolly Top Doctor, Castle Connolly, 2015-present
Commitment to Care, Amschwand Sarcoma Cancer Foundation, 2016

RESEARCH

Grants and Contracts

Funded

Principal Investigator, Cardiac Sarcoma Program, Maynard Family Foundation, 9/1/2015-present, \$5,500,000
Principal Investigator, Targeted and Cell based therapies for Cardiac Sarcoma, Maynard Family Foundation, 2019-present (\$5,000,000/year)

Protocols

Funded

Principal Investigator, A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST), 2008-0693, 2009, Novartis
Principal Investigator, Paclitaxel in combination with Bevacizumab (Avastin) for the treatment of metastatic or unresectable angiosarcoma, 2010-0309, 2010, Genentech
Principal Investigator, A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients with Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor, 2010-0608, 2012-2015, Novartis
Principal Investigator, An open label, multi-center nilotinib roll-over protocol for patients who have completed a previous Novartis sponsored nilotinib study and are judged by the investigator to benefit from continued nilotinib treatment., 2013-0234 (2008-0693GIST), 2013, Novartis
Principal Investigator, Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma, 2011-1202, 2013, NCI
Principal Investigator, A Phase III, Double-Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF), A091105, 2015, Alliance
Principal Investigator, Pilot Study of Efficacy of Oncology Dashboard in Improving Operational Efficiency and Patient Outcomes, 2014-0707, 2015, Phillips Healthcare
Principal Investigator, A Phase 1/2 Study of FPA008, an anti-CSF1 Receptor antibody, in Patients with Pigmented Villonodular Synovitis (PVNS)/Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT), 2015-0461, 2016, Five Prime Therapeutics
Principal Investigator, A Phase 2 Multi-Center Investigation of Efficacy of ABI-009 (Nabrapamycin in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (Pecoma), 2015-0945, 2016, AADi, LLC
Principal Investigator, A Randomized Phase 3 Trial of TRC105 and Pazopanib versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS), 2017-0063, 2017, TRACON Pharmaceuticals, Inc

Principal Investigator, A Phase 1 Trial of BC2059 (Tegavivint) in Patients with Unresectable Desmoid Tumor, 2018-0264, 2018-2025, \$169,030, Iterion

Principal Investigator, A Pilot study of Oraxol in subjects with cutaneous angiosarcoma, 2018-0332, 2018-2025, Athenex

Grant Reviewer/Service on Study Sections

Children Sarcoma Initiative Seed Money Grants, NIH, Member, 2014

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Ravi V, Hyland A, Cummings KM, Mahoney M. Associations Between Cancer Rates and Risk Factors by Region in New York State 1991-1994. *Journal of Cancer Education Suppl to Vol 15(3):39, Fall 2000, 7/2000.*
2. Ravi V, Wong MK. Strategies and Methodologies for Identifying Molecular Targets in Sarcomas and Other Tumors. *Current Treatment Options in Oncology 6(6):487-97, 2005, 6/2005.*
3. Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, Ravi V, Lazar AJ, Lev D. Outcome of Locally Recurrent and Metastatic Angiosarcoma. *Ann Surg Oncol 16(9):2502-9, 9/2009. e-Pub 6/2009. PMID: 19551444.*
4. Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, Garber J, Benjamin RS, Strom SS, Trent JC. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. *Ann Oncol. e-Pub 3/2010. PMID: 20348145.*
5. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. *Curr Opin Oncol 22(4):351-5, 7/2010. PMID: 20485168.*
6. Ravi V, Benjamin RS. Systemic therapy for cardiac sarcomas. *Methodist Deakey Cardiovasc J 6(3):57-60, Jul-Sep, 7/2010. PMID: 20834213.*
7. Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. *Head Neck 33(5):661-7, 5/2011. e-Pub 10/2010. PMCID: PMC4090937.*
8. Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. *Curr Opin Oncol 23(4):361-366, 7/2011. PMID: 21577109.*
9. Epner DE, Ravi V, Baile WF. When patients and families feel abandoned. *Support Care Cancer 19(11):1713-7, 11/2011. e-Pub 9/2010. PMID: 20853170.*
10. Katz D, Boonsirikamchai P, Choi H, Lazar AJ, Wang WL, Xiao L, Park MS, Ravi V, Benjamin RS, Araujo DM. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. *Clin Sarcoma Res 2(2):2, <http://www.clinicalsarcomaresearch.com/content/2/1/2>, 1/2012. e-Pub 1/2012. PMCID: PMC3351704.*
11. Yusuf SW, Bathina JD, Qureshi S, Kaynak HE, Banchs J, Trent JC, Ravi V, Daher IN, Swafford J. Cardiac tumors in a tertiary care cancer hospital: clinical features, echocardiographic findings, treatment and outcomes. *Heart Int 7(1):e4, 2/2012. e-Pub 2/2012. PMCID: PMC3366300.*
12. Ravi V, Patel S. Adjuvant chemotherapy for soft tissue sarcomas. *Surg Oncol Clin N Am 21(2):243-53, 4/2012. e-Pub 1/2012. PMID: 22365517.*
13. Raj SD, Zhou X, Bueso-Ramos CE, Ravi V, Patel S, Benjamin RS, Vadhan-Raj S. Prognostic Significance of Elevated D-Dimer for Survival in Patients with Sarcoma. *Am J Clin Oncol 35(5):462-7, 10/2012. e-Pub 6/2011. PMID: 21654313.*
14. Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, López-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJ. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. *Clin Sarcoma Res 2(1):25, 12/2012. e-Pub 12/2012. PMCID: PMC3599544.*
15. Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K, Chugh R, Morris GJ. A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. *Semin Oncol 40(2):135-44, 4/2013. PMID: 23540738.*

16. Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE. Long-Term Outcomes in Patients with Radiation-Associated Angiosarcomas of the Breast Following Surgery and Radiotherapy for Breast Cancer. *Ann Surg Oncol* 20(4):1267-74, 4/2013. e-Pub 12/2012. PMID: PMC5036516.
17. Hoffman A, Ghadimi MP, Demicco EG, Creighton CJ, Torres K, Colombo C, Peng T, Lusby K, Ingram D, Hornick JL, Wang WL, Ravi V, Lazar AJ, Lev D, Pollock RE. Localized and metastatic myxoid/round cell liposarcoma: Clinical and molecular observations. *Cancer* 119(10):1868-77, 5/2013. e-Pub 2/2013. PMID: 23401071.
18. Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. *Clin Sarcoma Res* 3(1):7, 5/2013. e-Pub 5/2013. PMID: PMC3660184.
19. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal marker and detection tool for human sarcoma circulating tumor cells. *Cancer Res* 74(6):1645-50, 3/2014. e-Pub 1/2014. PMID: PMC3959622.
20. Reardon MJ, Ravi V. Invited commentary. *Ann Thorac Surg* 97(4):1385-6, 4/2014. PMID: 24694414.
21. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N, Vollan HK, Papaemmanuil E, Koss H, Bunney TD, Hardy C, Joseph OR, Martin S, Mudie L, Butler A, Teague JW, Patil M, Steers G, Cao Y, Gumbs C, Ingram D, Lazar AJ, Little L, Mahadeshwar H, Protopopov A, Al Sanna GA, Seth S, Song X, Tang J, Zhang J, Ravi V, Torres KE, Khatri B, Halai D, Roxanis I, Baumhoer D, Tirabosco R, Amary MF, Boshoff C, McDermott U, Katan M, Stratton MR, Futreal PA, Flanagan AM, Harris A, Campbell PJ. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. *Nat Genet* 46(4):376-9, 4/2014. e-Pub 3/2014. PMID: PMC4032873.
22. Chavez AL, Singh P, Aleman AA, Anderson JE, Jernigan C, Ravi V. Tools to expedite the development of treatment plans. *Qual Manag Health Care* 23(2):70-5, Apr-Jun, 4/2014. PMID: 24710182.
23. Ramlawi B, Al-Jabbari O, Blau LN, Davies MG, Bruckner BA, Blackmon SH, Ravi V, Benjamin R, Rodriguez L, Shapira OM, Reardon MJ. Autotransplantation for the resection of complex left heart tumors. *Ann Thorac Surg* 98(3):863-8, 9/2014. e-Pub 7/2014. PMID: 25086947.
24. Hampras SS, Moysich KB, Marimuthu SP, Ravi V, Jayaprakash V. Socioeconomic factors and the risk for sarcoma. *Eur J Cancer Prev* 23(6):560-5, 11/2014. e-Pub 12/2013. PMID: 24356343.
25. Conter HJ, Gopalakrishnan V, Ravi V, Ater JL, Patel S, Araujo DM. Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience. *Sarcoma* 2014:375151, 2014. e-Pub 6/2014. PMID: PMC4082947.
26. Ravi V, Patel S, Benjamin RS. Chemotherapy for soft-tissue sarcomas. *Oncology (Williston Park)* 29(1):43-50, 1/2015. PMID: 25592207.
27. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. *Clin Chem* 61(3):544-53, 3/2015. e-Pub 1/2015. PMID: PMC4511273.
28. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Pihapaul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. *J Clin Oncol* 33(25):2753-62, 9/2015. e-Pub 5/2015. PMID: PMC4550690.
29. Dineen SP, Roland CL, Feig R, May C, Zhou S, Demicco E, Sanna GA, Ingram D, Wang WL, Ravi V, Guadagnolo A, Lev D, Pollock RE, Hunt K, Cormier J, Lazar A, Feig B, Torres KE. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. *Ann Surg Oncol* 22(12):3913-20, 11/2015. e-Pub 3/2015. PMID: PMC4561200.

30. Joseph J, Wang WL, Patnana M, Ramesh N, Benjamin R, Patel S, Ravi V. Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. *Clin Sarcoma Res* 5:22, 2015. e-Pub 10/2015. PMID: PMC4615364.
31. Ramlawi B, Leja MJ, Abu Saleh WK, Al Jabbari O, Benjamin R, Ravi V, Shapira OM, Blackmon SH, Bruckner BA, Reardon MJ. Surgical Treatment of Primary Cardiac Sarcomas: Review of a Single-Institution Experience. *Ann Thorac Surg* 101(2):698-702, 2/2016. e-Pub 10/2015. PMID: 26476808.
32. Roland CL, Boland GM, Demicco EG, Lusby K, Ingram D, May CD, Kivlin CM, Watson K, Al Sannaa GA, Wang WL, Ravi V, Pollock RE, Lev D, Cormier JN, Hunt KK, Feig BW, Lazar AJ, Torres KE. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. *JAMA Surg* 151(4):1-8, 4/2016. e-Pub 12/2015. PMID: PMC4941943.
33. Ravi V, Sanford EM, Wang WL, Ross JS, Ramesh N, Futreal A, Patel S, Stephens PJ, Miller VA, Ali SM. Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. *J Natl Compr Canc Netw* 14(5):499-502, 5/2016. PMID: 27160228.
34. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. *Sci Rep* 6:35448, 10/2016. e-Pub 10/2016. PMID: PMC5066200.
35. Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine Adenosarcoma: a Review. *Curr Oncol Rep* 18(11):68, 11/2016. PMID: 27718181.
36. Kamali F, Wang WL, Guadagnolo BA, Fox PS, Lewis VO, Lazar AJ, Conley AP, Ravi V, Toliyat M, Ladha HS, Hobbs BP, Amini B. MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumors. *Br J Radiol* 89(1058):20150308, 2016. e-Pub 11/2015. PMID: PMC4985189.
37. Gupta R, Heshami N, Jay C, Ramesh N, Song J, Lei X, Rose EJ, Carter K, Araujo DM, Benjamin RS, Patel S, Nates JL, Ravi V. Predictors of survival in patients with sarcoma admitted to the intensive care unit. *Clin Sarcoma Res* 6:12, 2016. e-Pub 7/2016. PMID: PMC4950117.
38. Wagner M, Ravi V, Sood AK. Endothelial cell malignancies: new insights from the laboratory and clinic. *npj Precision Oncology*. e-Pub 4/2017.
39. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. *Oncotarget* 8(24):39254-39267, 6/2017. e-Pub 4/2017. PMID: PMC5503611.
40. Abu Saleh WK, Ramlawi B, Shapira OM, Al Jabbari O, Ravi V, Benjamin R, Durand JB, Leja MJ, Blackmon SH, Bruckner BA, Reardon MJ. Improved Outcomes With the Evolution of a Neoadjuvant Chemotherapy Approach to Right Heart Sarcoma. *Ann Thorac Surg* 104(1):90-96, 7/2017. e-Pub 2/2017. PMID: 28189277.
41. Satcher RL, Ravi V, Wang WL, Oates S. Postpartum Treatment of Metastatic Recurrent Giant Cell Tumor of Capitate Bone of Wrist. *Am J Orthop (Belle Mead NJ)* 46(4):E269-E275, Jul/Aug, 7/2017. PMID: 28856360.
42. Leon-Castillo A, Chrisinger JSA, Panse G, Samdani RT, Ingram DR, Ravi V, Prieto VG, Wang WL, Lazar AJ. Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series. *J Cutan Pathol* 44(8):692-697, 8/2017. e-Pub 6/2017. PMID: 28556023.
43. Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. *Sci Rep* 7(1):9519, 8/2017. e-Pub 8/2017. PMID: PMC5573380.
44. Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest. *Mol Cancer Ther* 16(9):1751-1764, 9/2017. e-Pub 6/2017. PMID: 28619757.

45. Ikoma N, Torres KE, Lin HY, Ravi V, Roland CL, Mann GN, Hunt KK, Cormier JN, Feig BW. Recurrence Patterns of Retroperitoneal Leiomyosarcoma and Impact of Salvage Surgery. *J Surg Oncol* 116(3):313-319, 9/2017. e-Pub 5/2017. PMID: 28557016.
46. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. *Oncologist* 22(10):1271-1277, 10/2017. e-Pub 7/2017. PMID: PMC5634776.
47. Dembla V, Groisberg R, Hess K, Fu S, Wheeler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. *Sci Rep* 7(1):15963, 11/2017. e-Pub 11/2017. PMID: PMC5698336.
48. Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, Ravi V, Araujo D, Benjamin RS, Patel S, Vadhan-Raj S, Somaiah N. Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. *Sarcoma* 2017:7495914, 2017. e-Pub 9/2017. PMID: PMC5634608.
49. Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. *Clin Sarcoma Res* 7:11, 2017. e-Pub 6/2017. PMID: PMC5471883.
50. Nathenson MJ, Conley AP, Lin H, Fleming N, Ravi V. Treatment of Recurrent or Metastatic Uterine Adenosarcoma. *Sarcoma* 2017:4680273, 2017. e-Pub 12/2017. PMID: PMC5763139.
51. Khan JA, Maki RG, Ravi V. Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. *J Clin Oncol* 36(2):JCO2017749812, 1/2018. e-Pub 12/2017. PMID: 29220293.
52. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. *Oncotarget* 9(28):19891-19899, 4/2018. e-Pub 4/2018. PMID: PMC5929434.
53. Nathenson MJ, Conley AP, Lin H, Fleming N, Lazar A, Wang WL, Ravi V. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. *Int J Gynecol Cancer* 28(7):1297-1310, 9/2018. PMID: 30044322.
54. Ravi V, Leja M, Reardon MJ. A needle in a haystack. *J Thorac Cardiovasc Surg* 156(6):2204-2205, 12/2018. e-Pub 5/2018. PMID: 29908695.
55. Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. *N Engl J Med* 379(25):2417-2428, 12/2018. PMID: 30575484.
56. Bui N, Kamat N, Ravi V, Chawla S, Lohman M, Ganjoo KN. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma. *Rare Tumors* 10:2036361318771771, 2018. e-Pub 4/2018. PMID: PMC5946584.
57. Yanagawa B, Mazina A, Chan EY, Barker CM, Gritti M, Reul RM, Ravi V, Ibarra S, Shapira OM, Cusimano RJ, Reardon MJ. Surgery for Tumors of the Heart. *Semin Thorac Cardiovasc Surg* 30(4):385-397, Winter, 2018. e-Pub 9/2018. PMID: 30205144.
58. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. *Cancers (Basel)* 11(5), 5/2019. e-Pub 5/2019. PMID: PMC6562561.
59. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleiner E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. *Clin Cancer Res* 25(13):3802-3810, 7/2019. e-Pub 2/2019. PMID: PMC6606382.

60. Roszik J, Khan A, Conley AP, Livingston JA, Groisberg R, Ravi V, Carmagnani Pestana R, Sen S, Subbiah V. Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. *Cancers (Basel)* 11(9), 8/2019. e-Pub 8/2019. PMID: PMC6770224.
61. Konduri V, Halpert MM, Baig YC, Coronado R, Rodgers JR, Levitt JM, Cerroni B, Piscocoya S, Wilson N, DiBernardi L, Omarbekov Z, Seelhoff L, Ravi V, Douglass L, Decker WK. Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma. *Cancer Gene Ther* 26(9-10):282-291, 9/2019. e-Pub 1/2019. PMID: PMC6760631.
62. Ravi V, Reardon MJ. Commentary: Primary cardiac sarcoma-Systemic disease requires systemic therapy. *J Thorac Cardiovasc Surg.* e-Pub 10/2019. PMID: 31780067.
63. Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. *Cancer* 126(1):98-104, 1/2020. e-Pub 9/2019. PMID: 31536651.
64. Abbas HA, Amini B, Wang WL, Ravi V. Maneuvering the Management of a Rare Case of Primary Undifferentiated Cardiac Sarcoma. *Am J Case Rep* 21:e918878, 3/2020. e-Pub 3/2020. PMID: PMC7117855.
65. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. *J Immunother Cancer* 8(1), 3/2020. PMID: PMC7078933.
66. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. *Sarcoma* 2020:8363986, 2020. e-Pub 5/2020. PMID: PMC7285404.
67. Ali AMR, Tsai JW, Leung CH, Lin H, Ravi V, Conley AP, Lazar AJ, Wang WL, Nathenson MJ. The immune microenvironment of uterine adenocarcinomas. *Clin Sarcoma Res* 10:5, 2020. e-Pub 3/2020. PMID: PMC7103067.
68. Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, Tay TKY, Selvarajan S, Md Nasir ND, Loh JH, Ong CK, Huang D, Tan J, Li Z, Ng CC, Tan TT, Masuzawa M, Sung KW, Farid M, Quek RHH, Tan NC, Teo MCC, Rozen SG, Tan P, Futreal A, Teh BT, Soo KC. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. *J Clin Invest.* 2020 Nov 2;130(11):5833-5846. doi: 10.1172/JCI139080. PMID: 33016928; PMID: PMC7598061.
69. Chan EY, Ali A, Umana JP, Nguyen DT, Hamilton DJ, Graviss EA, Ravi V, MacGillivray TE, Reardon MJ. Management of primary cardiac paraganglioma. *J Thorac Cardiovasc Surg.* 2020 Oct 3:S0022-5223(20)32704-5. doi: 10.1016/j.jtcvs.2020.09.100. Epub ahead of print. PMID: 33148444.
70. Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. *Breast Cancer Res Treat.* 2021 Apr;186(3):871-882. doi: 10.1007/s10549-021-06116-8. Epub 2021 Feb 11. PMID: 33575859.
71. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.

- NPJ Precis Oncol. 2021 Mar 19;5(1):21. doi: 10.1038/s41698-021-00159-2. PMID: 33742104; PMCID: PMC7979841.
72. Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TW, Teterycz P, Baldi GG, Italiano A, Penel N, Brunello A, Duffaud F, Hindi N, Iwata S, Smrke A, Fedenko A, Gelderblom H, Van Der Graaf W, Vozy A, Connolly E, Grassi M, Benjamin RS, Broto JM, Grignani G, Jones RL, Kawai A, Tysarowski A, Mariani L, Casali PG, Stacchiotti S. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. *Cancer Med*. 2021 Apr;10(8):2645-2659. doi: 10.1002/cam4.3807. Epub 2021 Mar 13. PMID: 33713582; PMCID: PMC8026938.
 73. Wagner MJ, Lyons YA, Siedel JH, Dood R, Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, Wang WL, Ravi V, Holland EC, Sood AK. Combined VEGFR and MAPK pathway inhibition in angiosarcoma. *Sci Rep*. 2021 Apr 30;11(1):9362. doi: 10.1038/s41598-021-88703-9. PMID: 33931674; PMCID: PMC8087824.

Abstracts

1. Alfaro-Munoz K, Hallatt G, Sookprasong J, Yu E, Jin J, Futreal A, deGroot JF. Accelerating neuro-oncology research and improving patient care through a robust data foundation. Society for Neuro-Oncology Annual Scientific Meeting (#INNV-31), 2019.
2. Somaiah N, Conley AP, Lin H, Amini B, Sabir SH, Araujo DM, Benjamin RS, Livingston JA, Patel SR, Ravin R, Ravi V, Zarzour MA, Wang WL, Tate T, Roland CL, Daw N, Futreal A, Wistuba I. A Phase II Multi-Arm Study of Durvalumab and Tremelimumab for Advanced or Metastatic Sarcomas. 2020 Annual ASCO Virtual Meeting (#312479), 2020.
3. Subramaniam A, Zheng J, Yalamanchili S, Conley AP, Ratan R, Somaiah N, Livingston JA, Zarzour MA, Araujo DM, Benjamin RS, Patel SR, Ravi V. Modulation of YAP/TAZ by Statins to Improve Survival in Epithelioid Hemangioendothelioma (EHE). 2020 Annual ASCO Virtual Meeting, 2020.

Book Chapters

1. Raut CP, Ravi V, Patel S, DeLaney TF. Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy-II. In: UPTODATE. Basow, DS: Waltham, MA, <http://uptodate.com>, e-Book 2010.
2. Ravi V, Patel S. Desmoid Tumors: Systemic Therapy. In: UPTODATE. Ed(s) Basow, DS: Waltham, MA, <http://www.uptodate.com>, e-Book 2010.
3. Marcus M. Monroe, MD, Beverly A. Guadagnolo, MD, MPH, Vinod Ravi, MD, Wei-Lien Wang, MD, and Erich M. Sturgis, MD, MPH. Chapter 27: Sarcomas and Soft Tissue Tumors of the Head and Neck. In: Myers & Hanna, 2014.
4. Benjamin RS, Wagner MJ, Livingston JA, Ravi V, Patel SR. Chemotherapy for bone sarcomas in adults: the MD anderson experience. In: *Am Soc Clin Oncol Educ Book*. 35, e656-60, 2015. PMID: 25993237.
5. Ravi V, Patel S. Medical Management of Chondrosarcoma. In: *Bone Sarcoma*, part of the MD Anderson Cancer Series. Ed(s) Lin PP, Patel S. Springer: New York. In Press.

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editor, Scientific Reports, Nature Publishing Group, 2015-present

Other Editorial and Review Activities

Associate Faculty Member, Medicine Reports Limited, F1000, 2010-present

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

Instructor, Medical management of Soft tissue sarcomas
2/2009-present

Supervisory Teaching

Committees

Supervisory Committees

Clinical Research Mentor, Research Advisory Committee, Medical Oncology Fellowship Program, Michael Wagner, 7/2015-present

Direct Supervision

Medical Students

Research Mentor, Jason Joseph
Research Mentor, Rohan Gupta, PhD

Graduate Students

Research Mentor, Naveen Ramesh
Research Committee, Vijayashree Mokashi

Teaching Outside Current Institution

Formal Teaching

Courses Taught

Invited Lecturer, Healthcare Analytics, Jones School of Business at Rice University
2020-present

Direct Supervision

Medical Students

UTHSC, Aparna Subramamiam
UTHSC, Boomadevi Narendran

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

National Leiomyosarcoma Foundation, Houston, TX, Chair, 4/2016

Presentations at National or International Conferences

Invited

Hitting the Target: New Therapies for Molecularly Aberrant Sarcomas, ASCO Annual Meeting, 6/2013

Treatment of Cardiac Angiosarcoma, CIBR Short Talks, 8/2013

Tumor Registries and Rare Diseases, Texas Tumor Registrars Association, 9/19/2013

Whole Exome and Targeted Sequencing of Angiosarcomas: Target Identification and treatment implications., ASCO Annual Meeting, Chicago, IL, 5/2014

Systematic Therapy of Sarcomas, 15th National Conference of Bone & Soft Tissue Tumors, Tianjin, China, 5/23/2014

Sarcoma Update: 2016 Best of ASCO Review, American Society of Clinical Oncology and UT Health Science Center, San Antonio, San Antonio, TX, 6/18/2016

Cardiac Sarcomas, Beijing, China, 2019

Discussion of Strategies for Primary Tumors of Heart, Toronto, Canada, 2019

Understanding Angiosarcomas, 1st International Multidisciplinary Conference, Tel-Aviv, 2019

Other, Including Scientific Exhibitions

Ravi V, Cummings KM, Mahoney M. Associations Between Female Breast Cancer Rates and Mammography Utilization by Region in New York State, American Society of Preventative Oncology Annual Meeting, New York City, NY, 3/2001

Ravi V. Back Pain and Metastasis: An Atypical Presentation of Hepatocellular Carcinoma, ACP-AISM CT Chapter Meeting, 10/2002

Dim DC, Ravi V, Tan J, Hicks DG, Wong MK. The Actin Bundling Motility Protein Fascin and Vascular Endothelial Growth Factor (VEGF) are Universally Overexpressed in Human Angiosarcoma, ASCO Annual Meeting, 2007

Kishor Sakharpe A, Lahat G, Rao P, Ravi V, Hornick J, Lazar AJ, Lev D. Clinical and Molecular Insights into Epithelioid Sarcoma, CTOS Annual Meeting, Miami, FL, 11/2009

Nolden LK, Shum L, Dumont A, Patel S, Araujo DM, Ludwig JA, Ravi V, George S, Vadhan-Raj S, Benjamin RS, Trent JC. Steady-State Plasma Imatinib levels in 124 GIST patients: Distribution, Dose, Dose Escalation, and Response, CTOS Annual Meeting, Miami, FL, 11/2009

Anne Grand'Maison; Jeanne M. Meis; Robert S. Benjamin; Shreyaskumar Patel; Vinod Ravi. Impact of chemotherapy on survival in primary gastrointestinal angiosarcomas, Connective Tissue Oncology Society Annual Meeting, Salt Lake City, UT, 11/5/2015

Vinod Ravi, MD; Wei-Lien Wang; Alexander J. Lazar; Shreyaskumar Patel; Robert S. Benjamin. Metastatic potential of low and intermediate grade primary angiosarcomas of the breast: implications for neoadjuvant and adjuvant therapy, Connective Tissue Oncology Society Annual Meeting, Salt Lake City, UT, 11/5/2015

Daniela Katz; Heather Lin; Nikki Weaver; Jonathan Trent; Ariel Hammerman, PhD; Ilan Feldhamer; Dejka Araujo; Vinod Ravi; Anthony Conley; Wei-Lien Wang; Alexander Lazar; Shreyaskumar Patel; Robert Benjamin; Neeta Somaiah. Predicting response to second-line sunitinib (SU) based on duration of treatment on front-line imatinib (IM) in patients with metastatic GIST, Connective Tissue Oncology Society Annual Meeting, Salt Lake City, UT, 11/5/2015

Vivek Subbiah, MD; Pete Anderson; Winston W. Huh; VINOD RAVI; Kenneth Hess; Najat C. Daw; Joanna G. Fernandez; Neeta Somaiah; Gregory Ravizzini; Kamallesh Sankhala; Sant P. Chawla; Cindy L. Schwartz; David S. Hong; Eric Rohren. Safety and feasibility of alpha particle radium-223 dichloride therapy in high risk osteosarcoma: a phase 1 dose escalation trial, Connective Tissue Oncology Society Annual Meeting, Salt Lake City, UT, 11/5/2015

J. Andrew Livingston, MD; Michael J. Wagner; Anthony P. Conley; Vinod Ravi; Valerae O. Lewis; Patrick P. Lin; Shreyaskumar Patel; Robert S. Benjamin. Tailored post-operative therapy in adult osteosarcoma patients with poor necrosis: 30 years of treatment at MD Anderson cancer center, Connective Tissue Oncology Society Annual Meeting, Salt Lake City, UT, 11/5/2015

Michael J. Wagner, MD; J. Andrew Livingston; Vinod Ravi; Vancheswaran Gopalakrishnan; Shreyaskumar Patel; Alexander J. Lazar; Joseph Ludwig; Robert S. Benjamin. Vincristine, doxorubicin, and ifosfamide (VAI) for initial treatment of ewing sarcoma, Connective Tissue Oncology Society Annual Meeting, Salt Lake City, UT, 11/5/2015

Seminar Invitations from Other Institutions

Introduction to Cardio-Oncology, The Methodist Hospital System, Methodist DeBakey Heart & Vascular Center Grand Rounds, Houston, TX, 5/10/2012

Overview of Sarcoma Therapy, Medical Oncology and Hematology 2012: Clinical and Scientific Approaches that Enhance Patient Outcomes, MD Anderson Cancer Center, Houston, TX, 10/19/2012

Overview of Sarcoma Management, Christus Santa Rosa Health System, New Braunfels, TX, 2/22/2014

EHR Grand Rounds: Problem list oriented workflows in EPIC, M.D. Anderson Cancer Center, Houston, TX, 6/29/2016

Discussion of How Big Data is Changing the Field of Biomedical Research, Palantir GovCon 2018, Washington, 2018

Advancement of chemotherapy in soft tissue and bone sarcomas, 2018 Musculoskeletal Oncology Symposium, Milwaukee, 9/2018

Lectureships and Visiting Professorships

Understanding Angiosarcomas: Developing a translational research program in rare cancers, Duke-NUS Medical School, Medical Oncology, Singapore, Singapore, 6/3/2016

Other Presentations at State and Local Conferences

Back Pain and Spinal Metastasis, ACP-AISM CT, 10/2002

Ravi V. State of the Science: Where are we now with cytotoxic treatment options?, Janssen Biotech, University of Cincinnati and Creative Educational Concepts, Inc, Satellite Symposium, Salt Lake City, UT, 11/4/2015

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Association for Cancer Research
Associate Member, 2006-present

American Society of Clinical Oncology
Member, 2006-present

Connective Tissue Oncology Society
Member, 2006-present

DATE OF LAST CV UPDATE

9/14/2021